Therapeutic Effect Evaluation of Arsenious Acid-FOLFOX4 Combined Chemotherapy in Metastatic Liver Cancer_CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Authors：

ZHANG Yijun , WENG Yongqiang , QIU Jigang

Department of General Surgery, Huadong Hospital, Shanghai 200040, ChinaCorresponding Author: ZHANG Yi-jun, E-mail: doctor_zyj@hotmail.com;

Corresponding author：

Keywords：

Arsenious acid; Metastatic liver cancer; Combined chemotherapy; Therapeutic effect; Adverse reaction; FOLFOX4 program

Video：

Export PDF Favorites Scan Get Citation

Abstract Full text Figures/Tables Video References Cited by

　Objective 　To assess the value of arsenious acid in treatment for metastatic liver cancer and inspect its adverse reaction through comparison between the therapeutic effect of arsenious acid-FOLFOX4 combined chemotherapy and that of single FOLFOX4 chemotherapy.
　Methods 　Twenty-six patients with metastatic liver cancer were selected from July 2006 to December 2007 in Huadong Hospital. All the cases were averagely divided into therapy group and control group randomly, arsenious acid combined FOLFOX4 chemotherapy was performed in therapy group and single FOLFOX4 chemotherapy in control group.
　Results 　The total of 26 cases completed at least 2 cycles of arsenious acid-FOLFOX4 combined chemotherapy or single FOLFOX4 chemotherapy. During 6-24 months follow-up (median 12.5 months), the average survival time of the therapy group was 242 d, the median survival time was 281 d, and the average survival time of the control group was 227 d, the median survival time was 246 d, there was no statistical difference between two groups (P gt;0.05). Pain: There were 2 cases of complete remission (CR), 5 cases of partial remission (PR), 2 cases of stable disease (SD) in therapy group, the objective effect (CR+PR+SD) was 9 cases. There were 1 case of CR, 3 cases of PR, 2 cases of SD in control group, the objective effect (CR+PR+SD) was 6 cases. Objective efficacy: There were no CR cases in two groups. In therapy group, there were 5 cases of PR, 6 cases of NC, 2 cases of PD, the objective effect (CR+PR) was 5 cases, the benefit (CR+PR+NC) was 11 cases. In control group, there were 2 cases of PR, 4 cases of NC, 7 cases of PD, the objective effect (CR+PR) was 2 cases, the benefit (CR+PR+NC) was 6 cases. There was no significant difference of the objective effect between two groups (P gt;0.05), but the benefit was significantly different (P lt;0.05). The major toxic reactions were digestive tract side effect, hepatic and hematological toxicity in two groups.
　Conclusions 　Arsenious acid-FOLFOX4 combined chemotherapy can lead to good therapeutic effect. Arsenious acid will not increase the adverse reaction of normal chemotherapy.

Citation： ZHANG Yijun,WENG Yongqiang,QIU Jigang. Therapeutic Effect Evaluation of Arsenious Acid-FOLFOX4 Combined Chemotherapy in Metastatic Liver Cancer. CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY, 2010, 17(4): 348-351. doi: Copy

1.	Foster JH. Treatment of metastatic disease of the liver: a skeptic’s view [J]. Semin Liver Dis, 1984; 4(2): 170-179.
2.	刘向东，吴文娟，李海涛，等. 亚砷酸-碘油乳剂介入治疗原发性肝癌疗效分析 [J]. 介入放射学杂志, 2006; 15(12): 716-717.
3.	李志民，姜宇东，霍伟，等. 亚砷酸在原发性肝癌介入治疗中的疗效观察 [J]. 中国介入影像与治疗学, 2005; 2(5): 359-360.
4.	沈洁，金璋. 亚砷酸联合三维适形反射治疗原发性肝癌临床观察 [J]. 山东医药, 2008; 48(30): 71-72.
5.	赵文韬，王严庆，汤为学. 亚砷酸钠对人胃癌细胞株BGC-823的作用机制 [J]. 肿瘤防治研究， 2006; 33（5）： 733-734.
6.	刘静冰, 秦叔逵, 李进. 三氧化二砷注射液对胰腺癌细胞系PC-3的体外作用 [J]. 世界华人消化杂志, 2005； 13(14): 1713-1716.
7.	郑作琛, 饶健. 亚砷酸注射液治疗直肠癌术后复发获完全缓解1例 [J]. 临床肿瘤学杂志, 2001; 6(4): 376-381.
8.	张学彦，刘铁夫，刘伟，等. 亚砷酸诱导人食管癌细胞株EC109细胞p15INK4B基因的表达 [J]. 世界华人消化杂志, 2006; 14(19): 1859-1863.
9.	隋新华, 周晋, 孟然, 等. 三氧化二砷超声雾化吸入治疗肺癌的临床观察 [J]. 中国肿瘤临床与康复, 2004; 11(5): 419-421.
10.	Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [J]. J Natl Cancer Inst, 2000; 92(3): 205-216.
11.	钱军，秦叔逵，何泽明，等. 三氧化二砷治疗中晚期原发性肝癌的临床研究 [J]. 中华肝脏病杂志, 2002; 10(1): 63.
12.	Chan JY， Siu KP， Fung KP. Effect of arsenic trioxide on multidrug resistant hepatocellular carcinoma cells [J]. Cancer Lett， 2006; 236(2)： 250-258.
13.	项颖，黄凤鸣. 三氧化二砷注射液治疗中晚期原发性肝癌16例报告 [J]. 临床肿瘤学杂志, 2003; 8(1): 36-37.
14.	杨义明，张水兰，宋华勇，等. 亚砷酸联合干扰素治疗中晚期原发性肝癌的临床研究 [J]. 临床肿瘤学杂志, 2002; 7(5): 335-336.
15.	Oketani M, Kohara K, Tuvdendorj D, et al. Inhibition by arsenic trioxide of human hepatoma cell growth [J]. Cancer Lett, 2002; 183(2): 147-153.
16.	Tan B, Huang JF, Wei Q, et al. Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetaminodofluorene in rats [J]. World J Gastroenterol, 2005; 11(38): 5938-5943.
17.	华海清，秦叔逵，王锦鸿，等. 三氧化二砷抗肿瘤血管形成研究 [J]. 世界华人消化杂志, 2004; 12(1): 27-33.
18.	杜敏, 郭超, 唐兆杰, 等. 亚砷酸治疗实体恶性肿瘤的毒性反应观察 [J]. 药物不良反应杂志, 2004; 6(5): 306-308.

1. Foster JH. Treatment of metastatic disease of the liver: a skeptic’s view [J]. Semin Liver Dis, 1984; 4(2): 170-179.
2. 　刘向东，吴文娟，李海涛，等. 亚砷酸-碘油乳剂介入治疗原发性肝癌疗效分析 [J]. 介入放射学杂志, 2006; 15(12): 716-717.
3. 　李志民，姜宇东，霍伟，等. 亚砷酸在原发性肝癌介入治疗中的疗效观察 [J]. 中国介入影像与治疗学, 2005; 2(5): 359-360.
4. 　沈洁，金璋. 亚砷酸联合三维适形反射治疗原发性肝癌临床观察 [J]. 山东医药, 2008; 48(30): 71-72.
5. 　赵文韬，王严庆，汤为学. 亚砷酸钠对人胃癌细胞株BGC-823的作用机制 [J]. 肿瘤防治研究， 2006; 33（5）： 733-734.
6. 　刘静冰, 秦叔逵, 李进. 三氧化二砷注射液对胰腺癌细胞系PC-3的体外作用 [J]. 世界华人消化杂志, 2005； 13(14): 1713-1716.
7. 　郑作琛, 饶健. 亚砷酸注射液治疗直肠癌术后复发获完全缓解1例 [J]. 临床肿瘤学杂志, 2001; 6(4): 376-381.
8. 　张学彦，刘铁夫，刘伟，等. 亚砷酸诱导人食管癌细胞株EC109细胞p15INK4B基因的表达 [J]. 世界华人消化杂志, 2006; 14(19): 1859-1863.
9. 　隋新华, 周晋, 孟然, 等. 三氧化二砷超声雾化吸入治疗肺癌的临床观察 [J]. 中国肿瘤临床与康复, 2004; 11(5): 419-421.
10. 　Therasse P, Arbuck SG, Eisenhauer EA, et al. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada [J]. J Natl Cancer Inst, 2000; 92(3): 205-216.
11. 　钱军，秦叔逵，何泽明，等. 三氧化二砷治疗中晚期原发性肝癌的临床研究 [J]. 中华肝脏病杂志, 2002; 10(1): 63.
12. 　Chan JY， Siu KP， Fung KP. Effect of arsenic trioxide on multidrug resistant hepatocellular carcinoma cells [J]. Cancer Lett， 2006; 236(2)： 250-258.
13. 　项颖，黄凤鸣. 三氧化二砷注射液治疗中晚期原发性肝癌16例报告 [J]. 临床肿瘤学杂志, 2003; 8(1): 36-37.
14. 　杨义明，张水兰，宋华勇，等. 亚砷酸联合干扰素治疗中晚期原发性肝癌的临床研究 [J]. 临床肿瘤学杂志, 2002; 7(5): 335-336.
15. 　Oketani M, Kohara K, Tuvdendorj D, et al. Inhibition by arsenic trioxide of human hepatoma cell growth [J]. Cancer Lett, 2002; 183(2): 147-153.
16. 　Tan B, Huang JF, Wei Q, et al. Anti-hepatoma effect of arsenic trioxide on experimental liver cancer induced by 2-acetaminodofluorene in rats [J]. World J Gastroenterol, 2005; 11(38): 5938-5943.
17. 　华海清，秦叔逵，王锦鸿，等. 三氧化二砷抗肿瘤血管形成研究 [J]. 世界华人消化杂志, 2004; 12(1): 27-33.
18. 　杜敏, 郭超, 唐兆杰, 等. 亚砷酸治疗实体恶性肿瘤的毒性反应观察 [J]. 药物不良反应杂志, 2004; 6(5): 306-308.

CHINESE JOURNAL OF BASES AND CLINICS IN GENERAL SURGERY

Therapeutic Effect Evaluation of Arsenious Acid-FOLFOX4 Combined Chemotherapy in Metastatic Liver Cancer

Abstract Full text Figures/Tables Video References Cited by

Format

Content